Wednesday, July 1, 2015

The Anatomy of Healthcare Startups

Venture capital-backed healthcare startups are addressing diseases and conditions affecting virtually every part of the human body. 

Friday, June 19, 2015

NEW TITLES WITH FIRST JOURNAL IMPACT FACTOR. 2014 Release

Librarians and information scientists have been evaluating journals for at least 75 years. Gross and Gross conducted a classic study of citation patterns in the '20s. Others, including Estelle Brodman with her studies in the '40s of physiology journals and subsequent reviews of the process, followed this lead. However, the advent of the Thomson Reuters citation indexes made it possible to do computer-compiled statistical reports not only on the output of journals but also in terms of citation frequency. And in the '60s we invented the journal "impact factor." After using journal statistical data in-house to compile the Science Citation Index® (SCI®) for many years, Thomson Reuters began to publish Journal Citation Reports® (JCR®) in 1975 as part of the SCI and the Social Sciences Citation Index® (SSCI®).
Informed and careful use of these impact data is essential. Users may be tempted to jump to ill-formed conclusions based on impact factor statistics unless several caveats are considered. 
http://scientific.thomsonreuters.com/imgblast/JCR-newlist-2014.pdf

Tuesday, May 5, 2015

Happy World Pulmonary Hypertension Day 2015, everyone!

The recognition and declaration of a World Pulmonary Hypertension Day is a step forward in the consolidation of a worldwide PH awareness. World PH Day will focus on the importance of improving the quality of life and life expectancy of more than 25 million people living with PH worldwide. Pulmonary hypertension can be a fatal disease that is difficult to diagnose. There are many types of PH, including idiopathic and hereditary PH, which are considered rare diseases. However, PH is most commonly the result of other health problems.
Regardless of type, pulmonary hypertension is defined as an increase in blood pressure in the pulmonary artery, pulmonary veins or pulmonary capillaries, together known as the lung vasculature. It is a severe disease with a markedly decreased exercise tolerance; pulmonary hypertension can also eventually lead to heart failure.

 
https://www.youtube.com/watch?v=D4kn-H9zIMc

Objectives

During the celebration of World PH Day the patients' organizations will launch messages on the need to:
  • Increase awareness and disseminate knowledge of the disease to facilitate early diagnosis. Early diagnosis is important in decreasing premature PH-related deaths.
  • Promote access to specific healthcare and treatments that increase quality of life and life expectancy.
  • Promote the concept of treating PH patients as a whole, which includes treating their physical, psychological and social issues.
  • Unify international criteria for the recognition of Centers of Excellence in PH.
  • Promote research that will help find the cure for pulmonary hypertension.

Saturday, May 2, 2015

Pulmonary Hypertension Awareness 2015

Dear Respiratory Friends we are happy to introduce Chloe Temtchine, who is great fighter for Pulmonary Hypertension Awareness!
Chloe Temtchine's voice is clear, sultry and strong. She has pouty supermodel lips and high, perfectly arched brows. She's thin and tall with tan skin, and silky black hair. Chloe Temtchine wouldn't look out of place on any red carpet, maybe with the exception of the breathing tubes she uses, even while performing. 
https://www.youtube.com/watch?t=64&v=--f5fEIOW1Q

On April 3 Chloe Temtchine released her song "Be Brave," which she debuted at a Pulmonary Hypertension Association gala in New York City in November. The title of the song reminds us of the splendid courage it takes to live day to day with a disease or a disability. It reminds us that our perceptions of people should not be based on these factors, because that would only serve to disable them further.

Friday, May 1, 2015

Bronchiectasis Guidelines 2015

Dear Respiratory friends, today was published intresting review on Management of Bronchoectasis! 
Read full text: http://erj.ersjournals.com/content/45/5/1446.full
Formerly regarded as a rare disease, bronchiectasis is now increasingly recognised and a renewed interest in the condition is stimulating drug development and clinical research. Bronchiectasis represents the final common pathway of a number of infectious, genetic, autoimmune, developmental and allergic disorders and is highly heterogeneous in its aetiology, impact and prognosis.

The goals of therapy should be: to improve airway mucus clearance through physiotherapy with or without adjunctive therapies; to suppress, eradicate and prevent airway bacterial colonisation; to reduce airway inflammation; and to improve physical functioning and quality of life. 
http://erj.ersjournals.com/content/45/5/1446.full


Fortunately, an increasing body of evidence supports interventions in bronchiectasis. The field has benefited greatly from the introduction of evidence-based guidelines in some European countries and randomised controlled trials have now demonstrated the benefit of long-term macrolide therapy, with accumulating evidence for inhaled therapies, physiotherapy and pulmonary rehabilitation.

Tuesday, April 28, 2015

HRCT of fibrosing lung disease (free download)

The use of high-resolution computed tomography (HRCT) has brought increased diagnostic discrimination to the evaluation of lung disease, particularly fibrosing lung diseases.Once the presence of a predominantly fibrosing lung disease has been established on evaluation of a HRCT, a stepwise approach is proposed that can refine the potential HRCT diagnoses from a list of over 100 different interstitial lung diseases to one of only five fibrosing lung diseases.Within the category of the fibrosing lung diseases, the recognition of idiopathic pulmonary fibrosis (IPF) is key. IPF is the most prevalent idiopathic interstitial pneumonia and has a mortality greater than any of the other diffuse lung diseases. Several diagnostic dilemmas are explored including challenges with the recent IPF diagnosis and management guidelines (2011), as well as with the ‘difficult to characterize’ fibrosing diseases such as smoking-related lung fibrosis, unclassifiable disease and acute exacerbations of fibrosing lung disease.
free dowload:
http://www.readcube.com/articles/10.1111%2Fresp.12531
http://www.readcube.com/articles/10.1111%2Fresp.12531
 

Antimicrobial resistance in 2015 (free download)

Antimicrobial resistance (AMR) in humans is inter-linked with AMR in other populations, especially farm animals, and in the wider environment. The relatively few bacterial species that cause disease in humans, and are the targets of antibiotic treatment, constitute a tiny subset of the overall diversity of bacteria that includes the gut microbiota and vast numbers in the soil. However, resistance can pass between these different populations; and homologous resistance genes have been found in pathogens, normal flora and soil bacteria. Farm animals are an important component of this complex system: they are exposed to enormous quantities of antibiotics (despite attempts at reduction) and act as another reservoir of resistance genes. Whole genome sequencing is revealing and beginning to quantify the two-way traffic of AMR bacteria between the farm and the clinic. Surveillance of bacterial disease, drug usage and resistance in livestock is still relatively poor, though improving, but achieving better antimicrobial stewardship on the farm is challenging: antibiotics are an integral part of industrial agriculture and there are very few alternatives. Human production and use of antibiotics either on the farm or in the clinic is but a recent addition to the natural and ancient process of antibiotic production and resistance evolution that occurs on a global scale in the soil. Viewed in this way, AMR is somewhat analogous to climate change, and that suggests that an intergovernmental panel, akin to the Intergovernmental Panel on Climate Change, could be an appropriate vehicle to actively address the problem.
full text (free download): 
http://rstb.royalsocietypublishing.org/content/370/1670/20140083
http://rstb.royalsocietypublishing.org/content/370/1670/20140083